What question did this study set out to answer?

This study investigates the safety and effectiveness of BC008-1A, a bispecific antibody targeting PD-1 and TIGIT, in recurrent CNS WHO grade 4 glioma.

June 26, 2026

BC008-1A (PD-1/TIGIT bispecific antibody) in recurrent CNS WHO grade 4 glioma: Results from a randomized phase I study.

Key Points

This study investigates the safety and effectiveness of BC008-1A, a bispecific antibody targeting PD-1 and TIGIT, in recurrent CNS WHO grade 4 glioma.
Open-label, randomized phase I trial involving adults with recurrent CNS WHO grade 4 glioma.
Patients were randomized to receive BC008-1A in either 900 mg or 1200 mg doses every three weeks for 21-day cycles.
Primary endpoint assessed safety, while secondary endpoints evaluated overall response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).
Overall response rate (ORR) was 40% with 8 of 20 patients showing a partial response.
Best tumor shrinkage among responders reached 96.9%, with median time to response of 2.1 months.
No dose-limiting toxicities occurred, and only 16.7% reported grade ≥3 treatment-related adverse events.

Abstract

71 Background: Dual blockade of PD-1 and TIGIT may overcome T-cell exhaustion in glioma. BC008-1A is a humanized PD-1/TIGIT bispecific antibody. We report antitumor activity from two dose cohorts in recurrent CNS WHO grade 4 glioma. Methods: In this open-label, randomized phase I study, adults with histologically confirmed recurrent CNS WHO grade 4 glioma with RANO-confirmed progression after standard therapy, no surgical plan, KPS≥70, life expectancy ≥12 weeks, and ≥1 measurable intracranial lesion by RANO were randomized 1:1 to BC008-1A 900 mg or 1200 mg IV q3w (21-day cycles). Primary endpoint was safety (AEs/SAEs; TEAEs graded per NCI-CTCAE v5.0). Secondary endpoints included ORR/DCR, TTR, DOR, PFS and OS. Results: At data cutoff 22 Jan 2026, 20 patients were treated (900 mg 10; 1200 mg 10). Median age 54 years (range 21–67); IDH-wildtype 18/20. Safety: no DLTs; grade ≥3 TRAEs 16.7%; no serious TRAEs or treatment-related deaths. Efficacy: Median follow-up 5.6 months. Overall, PR 8/20 (ORR 40%), SD 5/20, PD 7/20 (DCR 65%). ORR was 50% (900 mg) and 30% (1200 mg). Best tumor shrinkage among responders reached 96.9% (range 81.9–96.9%). Median TTR was 2.1 months (range 0.7–4.1). DOR was up to 18 weeks, with 2 responses ongoing at cutoff. PFS events occurred in 6 patients. Conclusions: BC008-1A showed manageable safety and objective responses across 900–1200 mg in recurrent grade 4 glioma, supporting further evaluation with integrated PK and biomarker analyses. Clinical trial information: NCT06773481 .

Ask AI

Helpful

Bookmark